A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
Part of paid clinical trials in Jacksonville, Florida.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06647615
- Status
- Recruiting
Conditions
- Abdominal Pain (AP)
- Crohn's Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- VR headset — DEVICEThe VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
Study Details
The purpose of this research is to see if patients with Crohn's disease (CD) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (VR).
Key Dates
- Start date
- May 24, 2024
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: VR Headset
Primary Outcome Measure
Improvement in abdominal pain [ Time Frame: 10 weeks ]
Central Contacts
- Lauren P Loeb, MD904-953-6970
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | Jami Kinnucan, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Jacksonville, FL
By condition
By research site
Related Studies
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)PHASE3 · Recruiting · Takeda · Mobile, Alabama
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · Recruiting · AbbVie · Phoenix, Arizona
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseasePHASE4 · Recruiting · Takeda · Dothan, Alabama